Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series.

Anne Marie McKenzie-BrownDavid W BoormanKristen R IbanezEzihe Agwu Vinita Singh

Published in: Journal of pain research (2023)

Patients with all types of neuropathic pain, including CRPS, were significantly more likely to have pain relief from LDN than patients with spondylosis (p=0.018). The diagnosis of spondylosis was more often associated with a lack of response to LDN than any other diagnosis. Patients may need to have a trial of several weeks before analgesic effects are seen with LDN.

Keyphrases

neuropathic pain
chronic pain
spinal cord
low dose
spinal cord injury
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
pain management
high dose
study protocol
patient reported outcomes
phase iii
phase ii
patient reported